查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961042

全球側向層析檢測市場：市場規模、產業趨勢、機會分析及預測（2026-2035年），依產品/服務、適應症、技術、最終用戶、通路及地區劃分

Global Lateral Flow Assay Market: By Product & Services, Indications, Technique, End User, Distribution Channel, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 219 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球側向層析檢測（LFA）市場正經歷顯著成長，預計到2025年將達到約 108.4億美元。該成長趨勢預計將持續穩定推進，到2035年將成長至約 176.6億美元，2026年至2035年的年複合成長率約為 5.0%。市場擴張主要受幾個關鍵因素驅動，其中最顯著的是靈敏度不斷提高，接近實驗室等級，以及數位連接的整合。

先進技術與便攜性的結合對於未來分散式醫療保健非常重要，使在傳統實驗室環境之外也能進行快速且準確的診斷。以緊湊、易用的形式提供實驗室級的靈敏度，使醫護人員和患者能夠在各種環境下及時進行檢測，從診所到偏遠地區，甚至在家中。這種能力不僅透過快速診斷和治療改善患者預後，還透過實現廣泛的篩檢和監測，支持更廣泛的公共衛生措施。

市場趨勢

側向層析偵測市場的競爭格局高度集中，主要由 QuidelOrtho、Abbott和Roche等產業巨頭主導。這些領導企業憑藉其龐大的規模和深厚的監管專業知識，保持著市場主導地位。它們在從產品開發到監管合規等各個業務環節的高效運營，使其比規模較小的競爭對手擁有顯著優勢。例如，QuidelOrtho 公佈的2024年至今經常性收入為 17.4億美元，充分展現了其市場實力。

這些公司的優勢源自於它們能夠駕馭日益複雜和嚴格的診斷設備監管法規。例如，FDA 510（k）審批是產品上市的關鍵步驟，平均審批時間約 168.9 天，有效管理此流程需要豐富的專業知識、資源和策略規劃。像 QuidelOrtho、Abbott和Roche這樣的大公司擁有足夠的資金來應對漫長的審批流程，同時保持營運動力。

此外，這些公司在研發方面投入巨資，能夠不斷創新並拓展產品組合。龐大的研發預算使它們能夠推動新技術發展，提高檢測精度，並快速應對新出現的健康挑戰。這種雄厚的財力、監管敏銳度和創新能力的結合，不僅確保了它們的市場領導地位，也提高了小型公司的進入門檻。

核心成長驅動因子

新冠疫情後，醫療保健模式的重大重組塑造側向層析檢測市場的需求趨勢，並明顯轉向分散式檢測方法。全球醫療系統都在積極尋求緩解醫院壓力的方法，因為在傳染病爆發期間，醫院常常不堪負荷。這種策略轉變凸顯了快速即時診斷（POC）解決方案的重要性，這些解決方案可以在傳統臨床環境之外進行，加快決策速度並減少不必要的就醫。

新機會趨勢

改變側向層析檢測市場的最具創新性的趨勢之一是，人們不斷努力以便攜、易用的形式實現 "實驗室級的靈敏度" 。傳統上，側向層析檢測因其速度和便利性而備受青睞，但在靈敏度和準確性方面卻落後於實驗室方法。這項進步代表著重大飛躍。2024年，隨著基於CRISPR技術的側向層析檢測達到前所未有的0.25拷貝/μL的靈敏度閾值，這一差距開始顯著縮小。這一檢測水準對聚合酶鍊式反應（PCR）技術構成了挑戰，後者多年來一直主導著某些診斷應用，並有望在傳統實驗室環境之外實現快速、高靈敏度的檢測。

最佳化障礙

儘管側向層析檢測（LFA）因其快速出結果和易用性而廣受讚譽，但與更先進的實驗室方法（例如聚合酶鍊式反應（PCR）檢測）相比，其靈敏度和特異性通常有限。這種固有的挑戰可能導致假陽性或假陰性結果，這給醫護人員和患者都帶來了重大擔憂。假陽性結果會導致不必要的焦慮、額外的檢查和不恰當的治療，而假陰性結果則可能導致漏診和延誤治療，進而可能導致健康狀況惡化和傳染病傳播。

目錄

第1章 研究架構

  • 研究目標
  • 產品概述
  • 市場區隔

第2章 研究方法

  • 定性研究
    • 一手和二手資料來源
  • 量化研究
    • 一手和二手資料來源
  • 依地區劃分的一手調查受訪者組成
  • 研究假設
  • 市場規模估算
  • 資料三角驗證

第3章 執行摘要：全球側向流動免疫層析檢測市場

第4章 全球側向流動免疫層析檢測市場概要

  • 產業價值鏈分析
    • 原料供應商
    • 製造商
    • 服務提供者
    • 最終用戶
  • 行業展望
    • 即時診斷設備的各種應用
  • PESTLE 分析
  • 波特五力分析
    • 供應商議價能力
    • 買方議價能力
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度
  • 市場動態與趨勢
    • 成長驅動因素
    • 限制因素
    • 挑戰
    • 主要趨勢
  • 新冠疫情對市場的影響評估成長趨勢
  • 市場成長與展望
    • 市場收入估計與預測（2020-2035）
    • 依產品劃分的價格趨勢分析
  • 競爭格局概覽
    • 市場集中度
    • 公司市場佔有率分析（2025）
    • 競爭格局圖

第5章 側向層析檢測市場分析：依產品/服務劃分

  • 主要發現
  • 市場規模及預測，2020-2035
    • 閱讀器
    • LFA試劑盒

第6章 側向層析檢測市場分析：依適應症劃分

  • 主要發現
  • 市場規模及預測，2020-2035
    • 傳染病
    • 妊娠檢測
    • 藥物濫用檢測

第7章 側向層析檢測市場依技術分類分析

  • 主要發現
  • 市場規模及預測（2020-2035）
    • 夾心法檢測
    • 競爭法檢測
    • 多重檢測法檢測

第8章 側向層析偵測市場分析：依最終使用者

  • 主要發現
  • 市場規模及預測（2020-2035）
    • 醫院和診所
    • 診斷實驗室
    • 家庭醫療保健環境
    • 製藥和生技公司
    • 其他

第9章 側向層析偵測市場分析：依通路

  • 主要發現
  • 市場規模及預測（2020-2035）
    • 醫院藥房
    • 零售藥房
    • 超商/大型超市
    • 電子商務

第10章 側向層析檢測市場分析：依地區

  • 主要見解
  • 市場規模及預測（2020-2035）
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美

第11章 北美側向層析偵測市場分析

第12章 歐洲側向層析檢測市場分析

第13章 亞太地區側向層析偵測市場分析

第14章 中東與非洲側向層析檢測市場分析

第15章 南美洲側向層析檢測市場分析

第16章 公司簡介

  • Abbott Laboratories
  • bioMerieux S.A
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hologic Inc.
  • Merck KGaA
  • PerkinElmer Inc.
  • Qiagen N.V.
  • Quidel Corporation
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.,
  • Other Prominent Players
簡介目錄
Product Code: AA0522239

The global lateral flow assay (LFA) market is undergoing substantial growth, with its valuation reaching approximately USD 10.84 billion in 2025. This upward trajectory is expected to continue robustly, with projections estimating the market will expand to around USD 17.66 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of about 5.0% over the forecast period from 2026 to 2035. The expansion of the market is driven by several key factors, most notably the increasing integration of digital connectivity with enhanced assay sensitivity that approaches laboratory-grade performance.

This fusion of advanced technology and portability is critical to the future of decentralized healthcare, where rapid, accurate diagnostics can be performed outside traditional laboratory settings. The ability to deliver lab-quality sensitivity in a compact, user-friendly format empowers healthcare providers and patients alike to conduct timely testing in diverse environments, from clinics to remote locations and even at home. Such capabilities not only improve patient outcomes through faster diagnosis and treatment but also support broader public health initiatives by enabling widespread screening and monitoring.

Noteworthy Market Developments

The competitive landscape of the lateral flow assay market is largely consolidated, dominated by major industry players such as QuidelOrtho, Abbott, and Roche. These giants leverage their substantial scale and deep regulatory expertise to maintain a commanding presence in the market. Their ability to operate efficiently across multiple facets of the business-from product development to regulatory compliance-gives them a significant advantage over smaller competitors. For instance, QuidelOrtho has demonstrated its market strength with reported recurring revenues of USD 1.74 billion year-to-date in 2024.

The dominance of these companies is underpinned by their capability to navigate the increasingly complex and stringent regulatory pathways that govern diagnostic devices. For example, the average review time for FDA 510(k) clearance-a critical step for market authorization-stands at approximately 168.9 days, a process that requires significant expertise, resources, and strategic planning to manage effectively. Large players like QuidelOrtho, Abbott, and Roche are equipped with the capital necessary to endure these lengthy approval processes without compromising their operational momentum.

Moreover, these companies invest heavily in research and development, enabling them to innovate and expand their product portfolios. Their substantial R&D budgets allow them to advance new technologies, improve test accuracy, and respond rapidly to emerging health challenges. This combination of financial strength, regulatory acumen, and innovation capacity not only secures their market leadership but also creates high barriers to entry for smaller firms.

Core Growth Drivers

The demand trajectory of the lateral flow assay market is being shaped by a fundamental restructuring of healthcare models in the aftermath of the COVID-19 pandemic, with a clear shift toward decentralized testing approaches. Healthcare systems worldwide are actively seeking to alleviate the strain on hospitals, which have frequently been overwhelmed by surges in patient volume during infectious disease outbreaks. This strategic pivot emphasizes the importance of rapid, point-of-care (POC) diagnostic solutions that can be administered outside traditional clinical settings, enabling quicker decision-making and reducing unnecessary hospital visits.

Emerging Opportunity Trends

One of the most transformative trends reshaping the lateral flow assay market is the ongoing effort to achieve "lab-quality" sensitivity within a portable, easy-to-use format. This advancement represents a significant leap forward, as traditionally, lateral flow assays have been valued for their speed and convenience but have lagged behind laboratory methods in terms of sensitivity and accuracy. In 2024, this gap began to narrow considerably with the validation of CRISPR-based lateral flow assays that achieved an unprecedented sensitivity threshold of 0.25 copy/μL. This level of detection challenges the long-standing dominance of polymerase chain reaction (PCR) techniques in certain diagnostic applications, offering the potential for rapid, highly sensitive testing outside of traditional laboratory settings.

Barriers to Optimization

Lateral flow assays (LFAs), while widely appreciated for their rapid results and ease of use, often face limitations in sensitivity and specificity when compared to more sophisticated laboratory-based methods such as polymerase chain reaction (PCR) testing. This inherent challenge can result in false-positive or false-negative outcomes, which pose significant concerns for both healthcare providers and patients. False positives may cause unnecessary anxiety, additional testing, and inappropriate treatments, while false negatives carry the risk of missed diagnoses and delayed care, potentially exacerbating health conditions and contributing to the spread of infectious diseases.

Detailed Market Segmentation

By Product, the lateral flow assay market is fundamentally shaped by a high-volume "razor-and-blade" business model, which has resulted in lateral flow assay (LFA) kits commanding a dominant 71.9% share of the market. This model hinges on the continuous and recurring consumption of disposable test strips, which are essential for conducting individual diagnostic tests. While readers and software systems provide the necessary infrastructure to interpret and analyze test results, the bulk of the industry's revenue is generated from the steady demand for these single-use kits. This recurring revenue stream is crucial for sustaining the financial health of diagnostic manufacturers and fueling ongoing innovation within the sector.

By Indication, diagnosing infectious diseases represents the largest segment of the lateral flow assay market, capturing an impressive 72.2% share. This dominance reflects the critical role that lateral flow technology plays in the detection and management of infectious diseases worldwide, particularly during global health crises. The widespread adoption of these assays is driven not only by the seasonal surges of respiratory viruses such as influenza and COVID-19 but also by ongoing, large-scale international testing initiatives targeting endemic and high-burden infectious diseases.

By Technique, the sandwich assay technique holds a commanding position in the lateral flow assay market, controlling nearly 48% of the total share. This dominance is largely due to the method's scientific superiority and its suitability for detecting high-molecular-weight analytes, which represent some of the most commonly targeted substances within the industry. High-molecular-weight analytes often include vital proteins and biomarkers that are essential for diagnosing a wide range of diseases and conditions. Because these targets are prevalent and clinically significant, the sandwich assay format has become the preferred choice for many lateral flow applications.

By End Users, hospitals and clinics hold a dominant position in the lateral flow assay market, accounting for 38.8% of the total market share. This leadership is largely attributed to the preference within professional healthcare settings for higher-value, multiplexed diagnostic tests. These advanced assays can detect multiple analytes simultaneously, providing comprehensive diagnostic information that is crucial for managing complex medical conditions. Because of their sophistication and enhanced capabilities, these multiplexed diagnostics command significantly higher average selling prices (ASPs) compared to simpler home testing kits, making the hospital and clinic segment a highly valuable part of the market.

Segment Breakdown

By Product & Services:

  • Readers
  • Bench-top Readers
  • Hand-held Readers
  • LFA Kits
  • Test Strips
  • Dipsticks
  • Cassettes
  • Lancets

By Indications:

  • Infectious Diseases
  • Mosquito-borne Diseases
  • Streptococcus Infections
  • Sexually Transmitted Diseases
  • Hepatitis
  • Tuberculosis
  • Asthma
  • Pneumonia
  • Sepsis
  • Gastrointestinal Infections
  • Others
  • Pregnancy Test
  • Drug of Abuse Testing

By Technique:

  • Sandwich Assays
  • Competitive Assays
  • Multiplex Detection Assays

By End User:

  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Home Care Settings
  • Pharmaceuticals & Biotechnology Companies
  • Other

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Supermarkets/ Hypermarkets
  • e-Commerce

By Region:

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a commanding position in the lateral flow assay market, capturing a significant 34.90% share that is largely driven by the United States. This dominance is underpinned by the country's highly efficient regulatory framework and the pressing clinical demands placed on its healthcare system. The United States has established itself as a global leader in facilitating the rapid approval and deployment of diagnostic technologies, creating an environment that encourages innovation and swift market entry.
  • This regulatory agility is not merely a bureaucratic achievement but a direct response to urgent healthcare needs within the country. The U.S. faces a substantial clinical burden, exemplified by an estimated 40 million influenza cases annually and approximately 470,000 hospitalizations recorded in the most recent flu season. Such high incidence rates place enormous strain on healthcare resources, necessitating efficient and reliable diagnostic tools to manage patient flow and treatment decisions effectively.

Leading Market Participants

  • Abbott Laboratories
  • bioMerieux S.A
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hologic Inc.
  • Merck KGaA
  • PerkinElmer Inc.
  • Qiagen N.V.
  • Quidel Corporation
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.,
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Lateral Flow Assay Market

Chapter 4. Global Lateral Flow Assay Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Service Provider
    • 4.1.4. End-User
  • 4.2. Industry Outlook
    • 4.2.1. Various Applications of Point of Care Diagnostic Devices
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Bn), 2020 - 2035
    • 4.7.2. Price Trend Analysis, by product
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2025
    • 4.8.3. Competitor Mapping

Chapter 5. Lateral Flow Assay Market Analysis, By Product & Services

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 5.2.1. Readers
      • 5.2.1.1. Bench-top Readers
      • 5.2.1.2. Hand-held Readers
    • 5.2.2. LFA Kits
      • 5.2.2.1. Test Strips
      • 5.2.2.2. Dipsticks
      • 5.2.2.3. Cassettes
      • 5.2.2.4. Lancets

Chapter 6. Lateral Flow Assay Market Analysis, By Indications

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 6.2.1. Infectious Diseases
      • 6.2.1.1. Mosquito-borne Diseases
      • 6.2.1.2. Streptococcus Infections
      • 6.2.1.3. Sexually Transmitted Diseases
      • 6.2.1.4. Hepatitis
      • 6.2.1.5. Tuberculosis
      • 6.2.1.6. Asthma
      • 6.2.1.7. Pneumonia
      • 6.2.1.8. Sepsis
      • 6.2.1.9. Gastrointestinal Infections
      • 6.2.1.10. Others
    • 6.2.2. Pregnancy Test
    • 6.2.3. Drug of Abuse Testing

Chapter 7. Lateral Flow Assay Market Analysis, By Technique

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 7.2.1. Sandwich Assays
    • 7.2.2. Competitive Assays
    • 7.2.3. Multiplex Detection Assays

Chapter 8. Lateral Flow Assay Market Analysis, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 8.2.1. Hospitals & Clinics
    • 8.2.2. Diagnostics Laboratories
    • 8.2.3. Home Care Settings
    • 8.2.4. Pharmaceuticals & Biotechnology Companies
    • 8.2.5. Other

Chapter 9. Lateral Flow Assay Market Analysis, By Distribution Channel

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Retail Pharmacies
    • 9.2.3. Supermarkets/Hypermarkets
    • 9.2.4. e-Commerce

Chapter 10. Lateral Flow Assay Market Analysis, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. South Korea
      • 10.2.3.5. Australia & New Zealand
      • 10.2.3.6. ASEAN
      • 10.2.3.7. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Argentina
      • 10.2.5.2. Brazil
      • 10.2.5.3. Rest of South America

Chapter 11. North America Lateral Flow Assay Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 11.2.1. By Product & Services
    • 11.2.2. By Indication
    • 11.2.3. By Technique
    • 11.2.4. By End User
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country

Chapter 12. Europe Lateral Flow Assay Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 12.2.1. By Product & Services
    • 12.2.2. By Indication
    • 12.2.3. By Technique
    • 12.2.4. By End User
    • 12.2.5. By Distribution Channel
    • 12.2.6. By Country

Chapter 13. Asia Pacific Lateral Flow Assay Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 13.2.1. By Product & Services
    • 13.2.2. By Indication
    • 13.2.3. By Technique
    • 13.2.4. By End User
    • 13.2.5. By Distribution Channel
    • 13.2.6. By Country

Chapter 14. Middle East and Africa Lateral Flow Assay Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 14.2.1. By Product & Services
    • 14.2.2. By Indication
    • 14.2.3. By Technique
    • 14.2.4. By End User
    • 14.2.5. By Distribution Channel
    • 14.2.6. By Country

Chapter 15. South America Lateral Flow Assay Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 15.2.1. By Product & Services
    • 15.2.2. By Indication
    • 15.2.3. By Technique
    • 15.2.4. By End User
    • 15.2.5. By Distribution Channel
    • 15.2.6. By Country

Chapter 16. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 16.1. Abbott Laboratories
  • 16.2. bioMerieux S.A
  • 16.3. Bio-Rad Laboratories Inc.
  • 16.4. Danaher Corporation
  • 16.5. F. Hoffmann-La Roche Ltd.
  • 16.6. Hologic Inc.
  • 16.7. Merck KGaA
  • 16.8. PerkinElmer Inc.
  • 16.9. Qiagen N.V.
  • 16.10. Quidel Corporation
  • 16.11. Siemens Healthineers
  • 16.12. Thermo Fisher Scientific, Inc.,
  • 16.13. Other Prominent Players